Acthar Will Test Switch From Off- To On-Label Use At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel will decide whether re-analysis of trial data is enough to make Acthar treatment for infantile spasms on-label.
You may also be interested in...
New Challenge For Acthar Is Labeling; Practitioners Disagree On Dosing
Having gathered an advisory committee's endorsement that Questcor Pharmaceutical's Acthar (corticotropin) is effective for treating infantile spasms - a common off-label use - the remaining challenge for FDA is determining how the drug should be used in that indication
New Challenge For Acthar Is Labeling; Practitioners Disagree On Dosing
Having gathered an advisory committee's endorsement that Questcor Pharmaceutical's Acthar (corticotropin) is effective for treating infantile spasms - a common off-label use - the remaining challenge for FDA is determining how the drug should be used in that indication
Advisory Panelists' Experience Carries Weight In Acthar Debate
FDA's Peripheral and Central Nervous System Drugs Advisory Committee members cite their own use of the drug in voting that Acthar Gel is effective at treating infantile spasms.